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ORIGINAL RESEARCH
Abstract: The Australian Registry of Antiepileptic Drug Use in Pregnancy includes 172
instances in which women took sodium valproate, with or without other antiepileptic drugs,
during pregnancy. These pregnancies resulted in a substantially higher (p < 0.05) rate of
malformed offspring (15.1%) compared with 348 pregnant women who took antiepileptic
drugs other than valproate (2.3%) and 40 pregnancies in epileptic women who took no
antiepileptic drugs (2.5%). At valproate doses of 1400 mg and below per day, the mean rate of
pregnancies with fetal malformations was 6.42% and did not seem to be dose-dependent. At
higher valproate doses, the mean rate of pregnancy with fetal malformation was 33.9% and
appeared to increase with increasing drug dosage. This finding suggests the need for reappraisal
of the use of valproate in women who may become pregnant or are pregnant whilst the drug is
taken. The therapeutic policy adopted may depend on whether valproate doses below 1400 mg
per day are regarded as safe for the fetus. This study indicates that the risk of malformation
associated with such doses was just statistically significantly (p < 0.05) higher than that
associated with other antiepileptic drugs. Various possible clinical scenarios are discussed.
Keywords: epilepsy, malformations, pregnancy, valproate
Introduction
For over at least a third of a century, since the report of Meadow (1970) and other
early work reviewed by Janz (1976), the medical profession has been aware that the
intake of antiepileptic drugs (AEDs) in pregnancy is associated with an increased
risk of malformation in the offspring. This association has been confirmed repeatedly
in subsequent studies (Hart 2003). No specific patterns of malformation seem to
have been associated with any individual antiepileptic drug, although several reports
have suggested a particular association between valproate intake in pregnancy and
the occurrence of neural tube defects (Anon 1982; Nau and Hendrickx 1987; Omtzigt
et al 1992). Although the risk of malformations is now well documented for the
longer established AEDs, less information is available regarding the AEDs introduced
into therapeutics in the past decade. To address this, an Australian Pregnancy Registry
was set up in 1998 to recruit women nationwide on a volunteer basis. It recorded the
outcomes of pregnancy in those taking AEDs and also in women with untreated
epilepsy (Vajda et al 2003). The data in this Registry have been reviewed periodically.
Sufficient information on the outcome of pregnancies in which valproate has been
taken is now available. An assessment of these data and some of the questions it
raises are considered below.
Materials and methods
The Australian Registry of Antiepileptic Drug Use in Pregnancy depends on the
voluntary notification of women who take AEDs during pregnancy, those who are
suffering from epilepsy but do not take AEDs whilst pregnant, and those who take
AEDs whilst pregnant for indications such as pain or bipolar disorders (Vajda et al
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2003). Notification to the Registry may be initiated by the
treating medical practitioner or by the patient herself. Further
contact between the Registry and the patient is achieved by
telephone conversation rather than by face-to-face interview
because of the distances often involved between the patient’s
domicile and the Registry site. Registrants are interviewed
by telephone on two occasions during pregnancy (at entry
and at 7 months), within 1 or 2 months of giving birth, and
also at one year after childbirth. Although the majority of
patients have been enrolled before any investigation to
exclude fetal abnormality was carried out, it has not always
proved possible for patients to be notified to the Registry
before this stage. Indeed, some women have not been
notified to the Registry until after the outcome of the
pregnancy is known. Such delayed notifications have been
regarded as retrospective. The Registry data are stored in a
secure database held at the Australian Centre for Clinical
Neuropharmacology, Raoul Wallenberg Centre, The
University of Melbourne at St Vincent’s Hospital,
Melbourne. The Ethics Committee of St Vincent’s Hospital
has approved the research and undertaken primary ethical
responsibility for it. A small number of other local ethical
committees have also been involved.
For the purposes of the present paper, all the data in the
Registry relating to valproate use in pregnancy up to 31
December, 2003, have been analyzed, and some of the other
data in the Registry have been employed for comparison
purposes. Confidence interval (CI) analysis has been used
throughout in assessing the statistical significance of results.
Results
At the time of the current analysis, the Registry database
contained details of 560 completed pregnancies whose
outcomes were known, including the birth of 10 sets of
twins. In 520 of these pregnancies, AEDs had been taken,
nearly always for the indication of epilepsy. There were also
40 pregnancies in epileptic women who were not receiving
antiepileptic drug therapy who served as a control group.
Of the 520 pregnancies treated with AEDs, 348 had received
only AEDs other than valproate, and 172 had received
valproate (always as the sodium salt) either as their sole
antiepileptic agent (115 pregnancies) or in combination with
other AEDs (57 pregnancies).
Spontaneous abortions had occurred in 3 of the 172
pregnancies that were exposed to valproate and in 13 of the
348 pregnancies exposed to AEDs other than valproate: a
difference that was not statistically significant (1.74% vs
3.74%; odds ratio (OR) = 0.457: 95% CI = 0.129 – 1.63).
Therapeutic induced abortions occurred in 6 of the 172
pregnancies exposed to valproate, but were significantly less
frequent in the 348 pregnancies exposed to AEDs other than
valproate, occurring in only one instance (3.49% vs 0.29%;
OR = 12.5: 95% CI = 1.50 – 105). Four of the 6 induced
abortions in the valproate-exposed women were for spina
bifida detected prenatally. All of these induced abortions
for known fetal abnormality have been included in the fetal
malformation statistics to be discussed below. Stillbirths
occurred in 3 of the valproate-exposed pregnancies, and in
4 of the 348 pregnancies exposed to epileptic drugs other
than valproate (1.74% vs 1.15%; OR = 1.53: 95%
CI = 0.338 – 6.90).
Fetal malformations that were detected in utero,
recognized shortly after childbirth, or recognized at
interview one year later, were present in a total of 26 of the
172 pregnancies in which valproate was taken, but in only
8 of the 348 pregnancies exposed to AEDs other than
valproate (15.1% vs 2.30%; OR = 7.57: 95% CI = 3.35 –
 17.1). Pregnancies resulting in fetal malformations were
not statistically significantly more frequent amongst those
associated with valproate intake than in the 40 pregnancies
in the untreated epileptic women (15.1% vs 2.5%;
OR = 6.95: 95% CI = 0.914 – 52.8). Pregnancies with fetal
malformations occurred at very similar rates in women
exposed only to AEDs other than valproate and in the
untreated epileptic women (2.30% and 2.50%, respectively),
though it should be noted that only small numbers of
pregnancies not exposed to AEDs were available.
Five instances of spina bifida occurred in the valproate-
exposed pregnancies (2.9%). Various other malformations
involving different organ systems were encountered, whilst
multiple separate malformations occurred in 7 of the 26
valproate-exposed pregnancies with malformations. More
complete details are available elsewhere (Vajda et al 2004).
Pregnancies notified to the Registry after investigations
had already been done to exclude intrauterine fetal
abnormality, or notified only after the pregnancy was
completed, might have produced relatively selected
inclusion of pregnancies with abnormal fetal outcomes.
Therefore, rates of pregnancies resulting in fetal
malformations were also investigated in only the pregnancies
that had been included in the Registry prospectively. There
were 74 such valproate-exposed pregnancies and 148
pregnancies exposed to AEDs other than valproate. FetalTherapeutics and Clinical Risk Management 2005:1(1) 23
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malformations occurred in 11 of the 74 prospectively
notified valproate-exposed pregnancies, as compared with
1 of the 147 prospectively notified pregnancies exposed to
AEDs apart from valproate. This was still a statistically
significant difference in occurrence rates (15.1% vs 0.68%;
OR = 25.5: 95% CI = 3.22 – 202). However, it was not a
statistically significantly greater rate than the 1 in 40 rate in
untreated epileptic pregnancies (15.1% vs 2.5%; OR = 6.81:
95% CI = 0.846 – 54.8).
Fetal malformations occurred in 20 of the 115
pregnancies exposed to valproate but to no other antiepileptic
drug (ie, in valproate monotherapy), and in 6 of the 57
pregnancies exposed to valproate plus other AEDs (17.4%
vs 10.5 %; OR = 1.79: 95% CI = 0.676 – 4.74). This
difference in rates of pregnancies with fetal malformations
was not statistically significant. Of the pregnancies exposed
to valproate plus other antiepileptic drugs, lamotrigine was
the other major drug involved. Fetal abnormalities were not
more frequent with the valproate–lamotrigine combination
(3 instances) than with valproate alone (9.1% vs 17.4%;
OR 0.523: 95% CI = 0.146 – 1.87).
The effect of valproate dosage in the first trimester of
pregnancy on the rates of occurrence of pregnancies with
fetal malformations was examined by plotting the ratio of
such pregnancies to the cumulative number of pregnancies
exposed to valproate at or below a series of daily valproate
doses of increasing magnitude (Figure 1). For pregnancies
exposed to valproate alone and for all pregnancies exposed
to valproate, the rates of those with fetal malformations
remained about an average of 6%–7% until a threshold daily
valproate dose of 1400 mg was reached. Above that dose,
the rates of pregnancies with fetal malformations increased
in an apparent dose-dependent manner. For all pregnancies
exposed to valproate, the linear regression for malformation
rate on doses at or below 1400 mg per day (y = 4.294
+ 0.00185 dose; r
2 = 0.1414, p = 0.463) had a slope that was
not statistically significantly different from zero; however,
for doses above 1400 mg per day, the regression
(y = 8.234 + 0.00177 dose; r
2 =. 0674, p = 0.007) had a
statistically significant upwards slope and an elevation that
differed from that of the regression at lower doses
(p = 0.006). At valproate doses below 1400 mg per day there
were 7 pregnancies with fetal malformations in a total of
109 pregnancies (6.42%): at valproate doses above 1400 mg
per day, 19 of 56 pregnancies resulted in fetal malformations
(33.9%; OR = 0.134: 95% CI = 0.052 – 0.344). Figure 2
shows the rates of pregnancies with fetal malformations
among pregnant women exposed to valproate at a series of
dosage bands. This information is more relevant to the
situation of the individual pregnancy in which the drug is
taken. The fetal malformation risk after valproate exposure
at doses of 1400 mg per day or less (6.42%) was compared
with the risk in all pregnancies exposed to AEDs other than
valproate (8 in 348, ie, 2.30%). The difference in rates
(6.42% vs 2.30%) was just statistically significant
(OR = 2.92: 95% CI = 1.03 – 8.24). However, the fetal
malformed outcome risk (6.42%) at valproate doses of
1400 mg per day, or less, was not significantly different from
the 2.5% risk in the 40 untreated epileptic pregnancies
(OR = 2.68: 95% CI = 0.319 – 22.5). The point of particular
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Figure 1 Cumulative rates of occurrence of pregnancies with malformations below various threshold daily valproate doses.Therapeutics and Clinical Risk Management 2005:1(1) 24
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clinical importance that emerged from this aspect of the
study is that the relative risk of a malformed fetus in
valproate-exposed pregnancies, as compared with
pregnancies exposed to AEDs other than valproate, was
statistically significantly increased relative to the risk for
pregnancies exposed to AEDs other than valproate at all
valproate doses, achieving an overall value of 7.02 (95%
CI = 3.20 – 15.20) for all doses used. Further, the risk
appeared to increase progressively once valproate doses
exceeded 1400 mg per day.
The association between higher valproate doses and
increasing rates of pregnancies with fetal malformation
might have been due to higher drug doses being needed to
treat more difficult-to-control epilepsy, with this epilepsy
being responsible for the higher malformation rates.
Therefore, rates of pregnancies with fetal malformation were
compared in valproate-treated pregnancies in which bilateral
convulsive seizures had occurred in early pregnancy (3 of
23 such pregnancies yielding fetal malformations) and in
pregnancies free from convulsive seizures in their early
months (22 of 146 such pregnancies yielding fetal
malformations). The difference in rates (15.1% vs 13.0%;
OR = 0.845: 95% CI = 0.231 – 3.09) was not statistically
significant, suggesting that uncontrolled convulsive seizures
were not likely to explain the malformation risk situation in
valproate-exposed pregnancies.
The possibility of folic acid intake before or during
pregnancy contributing to the risk of fetal malformations
was assessed. No added folic acid had been taken in 10 of
the 26 valproate-exposed pregnancies that resulted in fetal
malformations, or in 47 of the 140 pregnancies exposed to
AEDs other than valproate that did not result in
malformations (38.5% vs 33.6 %; OR = 1.24: 95%
CI = 0.521 – 2.94). This result suggested that folic acid intake
probably did not protect against fetal malformations in
pregnancies exposed to valproate.
Discussion
The present study has shown that valproate intake during
pregnancy was associated with an apparently higher risk of
fetal malformations than in epileptic pregnancies not
exposed to AEDs; although, with small numbers being
involved in the untreated pregnancy group, the difference
was not statistically significant. Similar findings have
emerged from previous studies (Kaneko et al 1992,  1999;
Lindhout et al 1992; Kaneko and Kondo 1995; Samrén et al
1997, 1999; Morell 2003). However, the present study also
demonstrated that exposure to valproate during pregnancy
was associated with a significantly greater risk of fetal
malformation than that associated with exposure to other
AEDs in contemporary use. Earlier studies have sometimes
contained data that point in this direction (Kaneko et al 1999;
Samrén et al 1999), but this particular matter does not seem
to have been subjected to statistical analysis previously.
Although in the present study the fetal malformation risk in
pregnancies exposed to AEDs apart from valproate appeared
similar to that in untreated pregnancies in epileptic women,
the latter conclusion was of necessity, based on a small
dataset of untreated pregnancies and runs contrary to the
general trend in the literature. It would seem unwise to rely
on it unless it can be confirmed in a larger set of observations.
Various malformations, including spina bifida, were found














Figure 2 Rates of occurrence of pregnancies with malformations at various daily valproate doses.Therapeutics and Clinical Risk Management 2005:1(1) 25
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to have occurred in the present valproate-exposed
pregnancies, and folic acid intake did not seem to have
conferred any definite protection against their occurrence.
The present study also suggested that the rate of
pregnancies resulting in fetal malformation was relatively
steady at sodium valproate doses up to about 1400 mg per
day, but that there was a progressive and apparently dose-
related increase in the rate once the daily drug dose exceeded
this threshold. Such dose-dependence and an apparent cut-
off between relatively safer and relatively hazardous doses
of valproate have been noted by others (Samrén et al 1997,
1999; Kaneko et al 1999), who have set the cut-off at a dose
of 1000 mg per day. However, it is not always clear whether
this value referred to valproic acid, or to its sodium salt
with its higher molecular weight. An earlier analysis of the
portion of the present data that was then available found an
apparent cut-off at a sodium valproate dose of 1100 mg per
day (Vajda et al 2004). In the present study, there was a
statistically significantly higher fetal malformation rate
below the 1400 mg per day cut-off threshold for valproate
dose as compared with the rate for AEDs other than
valproate. However, there was no statistically significantly
higher rate if the malformation rate in untreated epileptic
pregnancies was used as the comparator. On the basis of
the present study, it is difficult to know whether doses of
valproate below 1000–1400 mg per day should be
considered safe from the fetal point of view. At this stage in
the accumulation of knowledge and until further collections
of data are available and analyzed, perhaps with assessment
of additional potential confounding factors, it may be
prudent to regard any valproate dose in pregnancy as
carrying more risk of fetal malformation than the risk of
malformation that accompanies other commonly employed
AEDs.
The existence of an apparent cut-off between a relatively
steady malformed fetal risk at lower valproate doses and a
progressively increasing risk at higher doses may seem
surprising. However, the predominant pathway for valproate
metabolism, at least in the non-pregnant state, tends to
change from fatty acid β-oxidation to O-glucuronidation at
about this same threshold dosage of valproate (Dickinson
et al 1989). At such a dosage the body’s β-oxidation capacity
towards the drug appears to approach saturation. Therefore
any additional valproate load may compete increasingly with
endogenous fatty-acid derived substrates of β-oxidation, and
accumulation of one or more of these substrates may harm
the fetus.
In view of the substantial overall risks of malformed
fetal outcomes associated with valproate exposure in
pregnancy, the issue of the drug’s use by pregnant women
needs to be reappraised. It should be recognized that the
following discussion is based on theoretical considerations
arising from the above studies, and that there is, as yet, no
evidence based on clinical experience that the courses of
action suggested below will prove safer or otherwise more
satisfactory for pregnant women or their offspring than
current therapeutic practice.
If valproate at doses below 1400 mg per day, or perhaps
1000 mg per day, is considered safe in pregnancy, it appears
reasonable to initiate therapy with the drug when it is
indicated in women of childbearing potential so long as the
dose can be kept below the increased malformation risk
threshold value. Should such a dose prove clinically
inadequate, another potentially suitable drug may be added
to the valproate, particularly if the valproate dose can be
reduced, or substituted. The data provided suggest that such
AED combination therapy is unlikely to increase the fetal
malformation risk. If ultimately there is no alternative but
to use higher valproate doses, the patient must be made
aware of the potential fetal hazards and the degree of risk,
based on data such as that contained in Figure 2. If pregnancy
is planned, and the valproate dose is below the threshold,
no further action is needed. Doses above the threshold need
to be reduced before pregnancy commences. If the dosage
reduction results in loss of seizure control, suitable
alternative AEDs may be added if they are available. If this
proves unsatisfactory, the patient must be prepared to accept
an increase in seizure frequency and perhaps severity whilst
pregnant, or resume the higher valproate dose and either
forego becoming pregnant, or accept the fetal malformation
risks. Should the patient present already pregnant, the
valproate dose should be reduced below what is believed to
be the heightened malformation risk threshold and, if
necessary, another drug added to control the patient’s
disorder. Prior to valproate dosage reduction, the patient
should be made aware of the risks and the social implications
of reduced seizure control. However, if the patient has
presented after the first trimester of pregnancy, it would
probably be too late for dosage reduction to benefit the fetus.
The data of Figure 2 then provide a basis for advising the
patient of the risk of malformation that exists and encourage
patients to have an appropriate management plan in place
for any subsequent pregnancy.
On the other hand, if valproate at any dose is regarded
as unacceptably hazardous for the fetus, it can be arguedTherapeutics and Clinical Risk Management 2005:1(1) 26
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that the drug should not be prescribed for females of child-
bearing potential until all suitable alternative agents have
been tried. This would be the case even for juvenile
myoclonic epilepsy or absence seizures, where valproate
would otherwise be the drug of first choice. If valproate
must be used its dose should be kept as low as possible. For
women taking valproate and planning pregnancy, it would
appear better to withdraw the drug and substitute an
alternative. If a woman taking valproate presents in her first
trimester of pregnancy, particularly if she presents early in
the trimester, or if the valproate dose is high, it would appear
preferable to cease intake of the drug quickly, though this
exposes the mother to hazards even though another AED is
substituted. Abrupt cessation of valproate intake should be
carried out in hospital to reduce the dangers of withdrawal
seizures and to permit more efficient treatment should they
occur. If the initial presentation occurs after the first trimester
of pregnancy, it would probably be too late for valproate
withdrawal to be beneficial.
There are several well established alternative agents
available with overall efficacies comparable to that of
valproate in the case of partial (localization-related) epilepsy.
In generalized epilepsies, where valproate is the most
effective remedy, the alternative options are more limited.
In disorders apart from epilepsy for which valproate might
be used during pregnancy (eg, migraine prophylaxis,
neuropathic pain, and bipolar disorder), principles similar
to those discussed above would apply, though adapted to
the different natural histories of the disorders being treated.
As further information accumulates, the considerations
relating to the issues discussed above may alter, and
decisions as to appropriate management may become easier
and more soundly based on actual experience rather than
on theoretical prediction. At the present time clinicians and
their female patients face difficult judgments in balancing
the advantages that valproate therapy may offer mothers or
potential mothers, the disadvantages that its withdrawal may
cause them, and the hazards its use may hold for their fetuses.
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